Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

American College of Cardiology's Annual Scientific Session (ACC.26)

is shedding additional light on the effects of tonlamarsen on 

Journal of the American College of Cardiology

, results demonstrate the investigational antisense oligonucleotide produced significant, dose-dependent reductions in plasma angiotensinogen among adults with uncontrolled hypertension on multiple antihypertensive medications, but failed to demonstrate additional blood pressure lowering with continued monthly dosing compared with a single dose followed by placebo.

“Because the drug was dosed monthly, we predicted that angiotensinogen would be fully back to its baseline levels by 20 weeks, but we found tonlamarsen’s effect was much longer acting than we would have predicted. The continued decrease in blood pressure after a single dose surprised us,” said Luke Laffin, MD, a cardiologist at Cleveland Clinic and the study’s lead author. “We also did not anticipate the finding that the percentage of angiotensinogen reduction didn’t necessarily correspond to blood pressure lowering 20 weeks out. This trial raises more questions than it gives answers at this point, but it gives us data that’s unique.”

Co-primary endpoints: percent change in plasma angiotensinogen and change in office systolic BP at week 20

Angiotensinogen decreased 67.2% with monthly dosing vs 23.0% with single dose (

<.0001); systolic BP change was -6.7 mm Hg in both arms (

Serious adverse events occurred in 5% of monthly-dosing arm vs 2.1% of single-dose arm; injection site reactions more frequent with ongoing dosing

KARDINAL was a multicenter, prospective, double-blind, placebo-controlled phase 2 trial conducted at 39 US sites between February and August 2025. The trial enrolled adults aged 18 years or older with office systolic blood pressure between 135 and 170 mmHg who were receiving stable doses of 2 to 5 antihypertensive agents. Key exclusion criteria included secondary hypertension, estimated glomerular filtration rate below 30 mL/min/1.73 m², and serum potassium greater than 5.1 mmol/L.

Following a 4-week placebo lead-in, all eligible participants received a single subcutaneous 90 mg dose of tonlamarsen during an active run-in period. Participants were then randomized 1:1 to either 4 additional monthly doses of tonlamarsen or matching placebo for 16 weeks. 

Of 519 patients screened, 206 received the active run-in dose and 198 were ultimately randomized: 100 to ongoing monthly tonlamarsen and 98 to single-dose tonlamarsen followed by placebo.

The overall study cohort had a mean age of 61 years, 49% were Black, 41% were female, and 82% were receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at baseline. The mean baseline office systolic blood pressure of the cohort was approximately 147 mmHg.

The coprimary endpoints were the between-group differences in percent change from baseline in plasma angiotensinogen and change in office systolic blood pressure at week 20.

AGT Suppression Diverged, Blood Pressure Did Not

At week 20, participants receiving monthly tonlamarsen demonstrated a least-squares (LS) mean reduction in plasma angiotensinogen of 67.2% (95% CI, -71.9 to -62.4) compared with 23.0% (95% CI, -27.8 to -18.2) among those receiving a single dose followed by placebo, a statistically significant between-group difference of -44.1% (97.5% CI, -51.9 to -36.4; 

However, the change in office systolic blood pressure was identical between arms at week 20. Specifically, a reduction of -6.7 mmHg was observed in both groups, yielding a between-group difference of -0.1 mmHg (95% CI, -4.5 to 4.4; 

= .97). No significant between-group differences were observed in home systolic blood pressure, office diastolic blood pressure, or proportion of participants achieving a systolic blood pressure below 130 mmHg.

The investigators noted the 23% residual suppression of angiotensinogen observed at week 20 in participants who received only 1 dose was unexpected given tonlamarsen's elimination half-life of 2 to 4 weeks. The persistence of angiotensinogen suppression in the placebo arm may have introduced a carryover effect confounded the blood pressure comparison between arms.

“One possibility, which we think is most likely, is that tonlamarsen lowers blood pressure by about 6-7 mmHg, and this is maintained even as angiotensinogen levels rise,” Laffin added. “Another possibility is that residual angiotensin suppression among placebo participants resulted in greater blood pressure reduction than expected. It’s also possible that decreasing angiotensin with tonlamarsen doesn’t reduce blood pressure, although we think that’s probably not likely based on the fact that blood pressure dropped during the drug run-in period.”

KARDINAL Safety Outcomes and Trial Limitations

Serious adverse events were infrequent and occurred in 2.1% of single-dose participants and 5.0% of those receiving ongoing tonlamarsen. A single death occurred in the monthly dosing arm and was assessed as unrelated to study drug by the site investigator. Injection site reactions were more common with multiple doses (19% vs 3%).

Trial investigators called attention to multiple limitations, including its active run-in design, which precluded a clean placebo comparator for assessing the true magnitude of blood pressure reduction. Additional limitations highlighted by investigators included its restriction to US sites, which may limit generalizability, and its modest sample size and short duration, which were insufficient to evaluate cardiovascular outcomes. Investigators suggested future trials should include a true placebo group without a tonlamarsen run-in.

Laffin LJ, Wang Q, Sarraju A, et al. Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial. 

American College of Cardiology. Investigational Drug Delivers Mixed Results for Uncontrolled Blood Pressure - American College of Cardiology. American College of Cardiology. Published March 28, 2026. Accessed March 28, 2026. 

https://www.acc.org/About-ACC/Press-Releases/2026/03/28/18/33/Investigational-Drug-Delivers-Mixed-Results-for-Uncontrolled-Blood-Pressure

Articles

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension. 

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Monthly Tonlamarsen Further Reduces Angiotensinogen, But Not Blood Pressure

Amy Sarma, MD, is the Cathy E. Minehan Endowed Chair in Cardiology and co-director of the Corrigan Women’s Heart Health Program and Cardiovascular Disease and Pregnancy Programs at the Massachusetts General Hospital.

Combatting Cardiovascular Risk in Postpartum and Menopausal Women

Women’s cardiovascular disease has long been a comparatively understudied sphere of cardiology as a whole – but in recent years, this sphere is positioned for a major reversal, particularly in such tumultuous times as postpartum and menopause.

American College of Cardiology (ACC) Scientific Sessions 2026

, the omnipresent issue of women’s access to cardiovascular care was again highlighted. In a series of presentations chaired in part by Amy Sarma, MD, co-director of the Corrigan Women’s Heart Health Program and Cardiovascular Disease and Pregnancy Programs at the Massachusetts General Hospital, as well as the Cathy E. Minehan Endowed Chair in Cardiology, the focus fell on 2 periods of women’s lives in particular, both of which are inherently transitory – the postpartum period and menopause.

“We’ve increasingly discovered that women are not just little men – we have unique sex-specific risk factors and differences in the types of cardiovascular conditions for which there is a greater susceptibility,” Sarma told 

 in an exclusive interview. “It’s very exciting that the ACC is increasingly covering topics highlighting these sex-specific differences – there’s a lot of excitement in this space that there hasn’t necessarily been in the past.”

A 2024 Scientific Statement from the American Heart Association (AHA) highlighted the risk of cardiovascular disease after adverse pregnancy outcomes, including 

, fetal growth restriction, and placental abruption. These conditions can directly influence the lifetime risk of 

atherosclerotic cardiovascular disease (ASCVD)

However, despite these associations, at the time of the statement’s writing, guidelines lacked recommendations to reduce cardiovascular disease risk and optimize health after adverse pregnancy outcomes. The fourth trimester, defined as the 12 weeks after delivery, is widely understood to be an optimal time for cardiovascular care to reduce maternal morbidity and improve transitions for postpartum patients.

Unlike the postpartum period, menopause is a physiologic event occurring in all women at roughly 52 years of age. Given the current life expectancy among women of 81 years, this results in roughly 1/3 of a woman’s life spent in menopause. Although women have a comparatively lower prevalence of cardiovascular disease than men, these rates exhibit a substantial increase after menopause, typically manifesting around 10 years after.

A 2021 review attempts to qualify this increase, attributing it largely to the similarly increased prevalence of adverse risk factors that often accompany menopause. These include insulin resistance, 

, fat redistribution, and other critical factors, the increase of all of which is thought to begin during the menopausal transition period.

Sarma spoke to the next steps cardiology should take to provide for women during these transitional periods of their lives. She highlighted more intensive and frequent screening for common cardiovascular risk factors, as well as increasing access to critical care among female patients.

“We need to think about being innovative in the way that we deliver care right now, particularly if we take, for example, the postpartum period,” Sarma said. “This is a period of time where we know that there are dynamic changes in the hemodynamics of patients, occurring on even a daily basis. While we routinely assess and reassess women during their pregnancy, their connection to care really falls off in that postpartum period where they remain at higher risk, but don’t have that same access to care.”

Editors’ Note: Sarma reports disclosures with King Pharmaceuticals, now part of Pfizer.

Lewey J, Beckie TM, Brown HL, et al. Opportunities in the Postpartum Period to Reduce Cardiovascular Disease Risk After Adverse Pregnancy Outcomes: A Scientific Statement From the American Heart Association. Circulation. 2024;149(7):e330-e346. 

Nair AR, Pillai AJ, Nair N. Cardiovascular Changes in Menopause. Curr Cardiol Rev. 2021;17(4):e230421187681. 

Videos

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

Strategic Alliance Partnership

Combatting Cardiovascular Risk in Postpartum and Menopausal Women, With Amy Sarma, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

1 Year Data Supports Icotrokinra Versus Deucravacitinib for Psoriasis, With Linda Stein Gold, MD

Sustained Itch Reduction Observed at 1 Year of Icotrokinra in Psoriasis, With Linda Stein Gold, MD

One-year findings from a pair of pivotal phase 3 trials have been presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 reinforce icotrokinra's emerging profile as a high-efficacy oral option for adults with moderate-to-severe plaque psoriasis, and these data suggest the targeted oral peptide may offer certain advantages over deucravacitinib.

 at AAD, trial investigator Linda Stein Gold, MD, of Henry Ford Health, highlighted key results from ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604) studies. These are 2 phase 3 analyses assessing icotrokinra not only against placebo but also in a direct head-to-head comparison with deucravacitinib, which Stein Gold noted was considered the benchmark for oral psoriasis drugs.

“We looked at these head to head, three different arms of the study, and then those patients who were on placebo were transitioned to oral [icotrokinra],” Stein Gold explained.

Adults with moderate-to-severe psoriasis were involved in 3 arms: once-daily oral icotrokinra 200 mg, placebo (transitioning to icotrokinra at the 16-week mark), and deucravacitinib 6 mg (transitioning to icotrokinra at Week 24). Stein Gold et al had tracked Investigator's Global Assessment (IGA) and Psoriasis Area and Severity Index (PASI) responses through Week 52.

In her interview, Stein Gold described icotrokinra demonstration of a rapid onset of action, noting the sustained improvement maintained across the full 52-week observation period. The depth of response in skin clearance was also noted, as early in the studies, those on icotrokinra attained a clear level of skin at roughly double the rate of those on deucravacitinib.

When deucravacitinib-treated individuals crossed over to icotrokinra at the 24-week mark, these patients’ clearance rates similarly doubled, and those gains held through Week 52. Additionally, the drug’s safety profile was strong, with the adverse event (AE) rates with icotrokinra being comparable to placebo. Stein Gold and colleagues also found infection rates came in numerically lower than those observed with deucravacitinib.

The trials also enrolled adolescent patients alongside adults, and tolerability findings were noted as consistent across age cohorts. Overall, optimism regarding icotrokinra's study program’s continuation was expressed by Stein Gold.

Disclosures: Stein Gold reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis. Johnson & Johnson. March 28, 2026. 

https://www.jnj.com/media-center/press-releases/icotyde-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-once-daily-pill-for-plaque-psoriasis

Campbell P. Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis. HCPLive. March 18, 2026. Accessed March 28, 2026. 

https://www.hcplive.com/view/icotrokinra-receives-fda-approval-for-psoriasis

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Nearly 9 in 10 patients with biologic-naïve psoriatic arthritis (PsA) treated with risankizumab (Skyrizi; AbbVie) showed no radiographic progression over approximately 5 years of follow-up, according to a post hoc analysis of the phase 3 KEEPsAKE 1 trial presented at the 

 held in Denver, Colorado, from March 27-31.¹

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks, marking the longest such follow-up reported from the KEEPsAKE program, and reinforce prior evidence of durable structural protection in this population.

KEEPsAKE 1 (NCT03675308) is a phase 3, randomized, double-blind study of risankizumab 150 mg versus placebo in adults with active PsA and inadequate response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD). After an initial 24-week double-blind period, all patients entered an open-label extension receiving risankizumab 150 mg every 12 weeks through week 316.¹

In the current post hoc analysis, investigator Sarah Lonowski, MD, MBA, Assistant Professor, UNMC Department of Dermatology, and colleagues, focused on the n = 483 patients initially randomized to risankizumab, tracking radiographic outcomes assessed by the modified Total Sharp Score (mTSS) — a composite measure of joint erosion and joint space narrowing in the hands, wrists, and feet, scored from 0 to 528. Radiographs were obtained at baseline and at weeks 24, 52, 100, 148, 196, and 244. The primary measure of interest was radiographic nonprogression, defined as a change from baseline in mTSS of ≤0, reported as observed. A subgroup analysis examined whether patients free of radiographic progression at week 52 sustained that outcome through week 244.¹

Baseline characteristics reflected a csDMARD-inadequate-response population with meaningful disease burden: mean disease duration was 7.1 years, mean swollen joint count was 12.1, and mean baseline mTSS was 13.0.¹

Across the full 244-week observation period, mean change from baseline in mTSS remained minimal in the risankizumab arm, increasing from 0.03 at week 24 to 0.93 at week 244 — a modest absolute change over approximately five years of follow-up.¹ The proportion of patients with no radiographic progression (mTSS change ≤0) was 88.4% at week 244, remaining generally stable across all assessed timepoints.¹

The maintenance of nonprogression analysis examined patients who were already nonprogressors at week 52 — a prespecified subgroup intended to capture those who established early structural protection. Among this cohort, mean change from baseline in mTSS remained minimal through week 244 (0.25), and 93.4% remained nonprogressors at week 244.¹

The authors noted that safety was not assessed in this analysis but referenced the overall KEEPsAKE 1 safety record, which has shown risankizumab to be generally well-tolerated with no new signals through 244 weeks.¹

The analysis carries a significant methodological caveat: as a post hoc analysis, it was not powered to detect statistically significant differences between progressors and nonprogressors in rates of structural damage or mTSS scores. Additionally, changes from baseline in mTSS were not statistically different between risankizumab and placebo at week 24, which was a ranked secondary endpoint in KEEPsAKE 1.¹ The nonprogression proportions reported here were a prespecified but nonranked endpoint, meaning no formal statistical conclusions can be drawn. Findings should be interpreted in that context.

Structural joint damage in PsA is cumulative and, once established, irreversible. Joint erosion and joint space narrowing, both captured by mTSS, can impair physical function and contribute to long-term disability, underscoring the clinical importance of sustained radiographic protection beyond early trial endpoints.

The 5-year KEEPsAKE 1 data add to a growing body of long-term evidence for risankizumab in PsA. The combined 196-week analysis of KEEPsAKE 1 and KEEPsAKE 2, published in 

 in 2025, reported durable ACR20, minimal disease activity, and skin response through approximately 4 years of follow-up, with a consistent safety profile and no new signals across both csDMARD-IR and biologic-IR patient populations.² The 244-week radiographic data presented at AAD 2026 now extend that structural picture by an additional year.

The data are also contextually relevant given the current competitive landscape in PsA. Earlier this month, UCB announced that bimekizumab (Bimzelx) demonstrated superiority over risankizumab on ACR50 at week 16 in the head-to-head BE BOLD trial — the first superiority result by a licensed biologic over an IL-23 inhibitor in PsA.

 Long-term structural data from KEEPsAKE 1, while carrying the limitations noted above, represent an evidence base that head-to-head efficacy data at a single timepoint do not address.

Lonowski S, Khattri S, Talia J, et al. Long-term efficacy of risankizumab in maintenance of radiographic nonprogression in patients with active psoriatic arthritis: 5-year data from the KEEPsAKE 1 phase 3 trial. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster DV-018384.

Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 196-week results from the KEEPsAKE 1 and KEEPsAKE 2 randomized clinical trials. 

 2025;12(6):1103–1123. doi:10.1007/s40744-025-00793-3

Johnson V. Bimekizumab Beats Risankizumab on PsA ACR50 in Preliminary Head-to-Head Data. Article. RheumatologyLive. March 11, 2026. 

https://www.rheum-live.com/view/bimekizumab-beats-risankizumab-psa-acr50-preliminary-head-to-head-data

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

KEEPsAKE-1: Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD

Rezpegaldesleukin, a novel regulatory T-cell agonist, has demonstrated statistically significant hair regrowth in severe-to-very-severe alopecia areata, establishing proof of concept for what may become the first targeted biologic to receive an indication in a disease where JAK inhibitors have been the only approved advanced option.

The data, from the phase 2b REZOLVE-AA study (NCT06340360), were presented as a late-breaking oral presentation at the 

 held in Denver, Colorado, from March 27-31, by David Rosmarin, MD, Chair of the Department of Dermatology and Associate Professor of Dermatology at Indiana University School of Medicine in Indianapolis. 

spoke with Rosmarin during the meeting to learn more about the study, which enrolled 92 adults with severe-to-very-severe alopecia areata (SALT ≥50) who had not previously received a JAK inhibitor or biologic. Participants were randomized 3:3:2 to rezpegaldesleukin 18 µg/kg every two weeks (n = 37), 24 µg/kg every two weeks (n = 35), or placebo (n = 20) for 36 weeks, with stratification by baseline SALT ≥50 to <95 versus ≥95 to 100. Mean baseline SALT scores were 80.7, 76.3, and 76.6 across the 3 arms, respectively.

On the primary endpoint of mean percent SALT reduction at week 36, both active arms demonstrated approximately 30% mean reduction versus 6% for placebo — achieving statistical significance (

 <.05) in a modified ITT analysis excluding 4 patients with major eligibility violations, with the 24 µg/kg dose showing statistically significant separation from placebo at every timepoint from week 12 through week 36.

In the secondary analyses, SALT ≤30 was achieved by 29.0% and 21.9% of patients in the 24 µg/kg and 18 µg/kg arms versus 8.4% for placebo; SALT ≤20 by 15.6% and 14.8% versus 6.7%; and SALT ≤10 by 11.5% and 8.3% versus 0.7%. Eyebrow and eyelash regrowth were also observed, with placebo-adjusted ClinRO response rates of 15% and 18% for eyebrows and eyelashes, respectively, in the 24 µg/kg arm.

Rosmarin emphasized that efficacy showed no plateau at week 36, a meaningful observation given the large number of partial responders still on treatment — and 16-week extension data expected in April 2026 may capture additional responders. The safety profile was consistent with over 1,000 patients exposed across 11 studies; the most common adverse events were mild-to-moderate injection site reactions (91.7% combined rezpegaldesleukin arms vs. 30.0% placebo) and eosinophilia (6.9% vs. 0%), with no increased rates of serious infections, MACE, thrombosis, or malignancy.

In our conversation, Rosmarin described the mechanistic rationale as genuinely differentiated — rezpegaldesleukin's selective pegylation allows preferential expansion of Tregs over effector T cells at therapeutic doses, a distinction that avoids the pro-inflammatory activity seen with native IL-2 at higher concentrations, and 1 recognized by the 2025 Nobel Prize in Physiology or Medicine. He noted that Nektar Therapeutics is planning a phase 3 program at the 24 µg/kg dose.

“I have high confidence that [the phase 3 study] will be positive and lead to ultimate FDA approval,” Rosmarin said.

Rosmarin’s disclosures include AbbVie, Abcuro, Ability Biologics, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Dualitas, Edesa Biotech, EMD Serono, Forte Biosciences, Galderma, Incyte, Inmagene, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, Phothera, RAPT, Recludix, Regeneron, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, Takeda, UCB, VielaBio, and Zura Bio.

Rosmarin D, Ungar B, Mesinkovska N, et al. Novel regulatory T-cell enhancing biologic rezpegaldesleukin: phase 2b efficacy and safety results following 36-weeks of therapy in severe-to-very-severe alopecia areata (REZOLVE-AA). Oral late-breaking presentation presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Abstract 79863.

Nektar Therapeutics. Data from phase 2b REZOLVE-AD and REZOLVE-AA studies of rezpegaldesleukin presented at 2026 American Academy of Dermatology Annual Meeting. Press release. March 28, 2026. 

https://www.prnewswire.com/news-releases/data-from-phase-2b-rezolve-ad-and-rezolve-aa-studies-of-rezpegaldesleukin-presented-at-2026-american-academy-of-dermatology-annual-meeting-302727838.html

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

Alopecia

First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Late-Breaking Data Highlight Nemolizumab Efficacy in Children with Atopic Dermatitis

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes. 

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Ultrasound-Facilitated Catheter-Directed Fibrinolysis Reduces Early Decompensation in Pulmonary Embolism

Arrhythmia

CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

Petter Bjornstad, MD, is executive director of the UW Medicine Diabetes Institute, professor of pediatrics and medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

REMODEL: Mechanistic Insights Into Semaglutide in CKD, With Petter Bjornstad, MD

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

KDIGO updates in IgA nephropathy highlight lower proteinuria targets, improved risk tools, and an expanding landscape of targeted and combination therapies.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

IgAN Risk, Proteinuria Targets, and KDIGO Updates, With Chee Kay Cheung, MBChB, PhD

Michelle Bichchau Nguyen, MD, MBA, MPH, is an associate professor of dermatology at Tufts University School of Medicine and the director of Mohs Micrographic Surgery.


This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.

What Are the Biggest Drivers of Dissatisfaction in Dermatology? With Michelle Nguyen, MD, MBA, MPH

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tildrakizumab Sustains Nail Psoriasis Efficacy Through 52 Weeks in Phase 3b Extension Data

This interview at AAD 2026 highlights tips for clinicians in dermatology practices who want to improve patient communication and satisfaction.

Ways to Improve Patient Experience with Surgery in Dermatology, With Michelle Nguyen, MD, MBA, MPH

Abdallah Geara, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.

Corey Cavanaugh, DO, and Abdallah Geara, MD, separately share their perspectives on the clinical clues for IgAN diagnosis, including hypertension and microscopic hematuria.

Latest News

Monthly Tonlamarsen Further Reduces Angiotensinogen, But Not Blood Pressure

Combatting Cardiovascular Risk in Postpartum and Menopausal Women, With Amy Sarma, MD

Sustained Itch Reduction Observed at 1 Year of Icotrokinra in Psoriasis, With Linda Stein Gold, MD

KEEPsAKE-1: Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD